Emtricitabine, Rilpivirine, Tenofovir Disoproxil vs Abacavir — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Emtricitabine, Rilpivirine, Tenofovir Disoproxil

First FDA approval: 2025-05-27

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Abacavir

Brand: Abacavir

First FDA approval: 1999-01-28

Lowest NADACAcquisition cost floor across all NDCs

$114.86Per unit

$0.652Per unit

Average NADACAcross all dosage forms and strengths

$114.86Up to $114.86

$0.652Up to $0.652

Generic manufacturersActive ANDA holders — FDA Orange Book

22 total ANDAs filed

57 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$4.2MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

23K4K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$180Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes2 manufacturers

Yes5 manufacturers